{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-23-000058","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.929682+00:00","generated_at":"2026-06-18T01:40:28.685236+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MacroGenics reports 2022 net loss of $119.8M; cash runway extended through 2025 via $250M non-dilutive funding","bullets":["Net loss $119.8M ($1.95/share) vs $202.1M in 2021; revenue $151.9M (up 96% YoY).","Cash $154.3M at Dec 2022; plus $100M from DRI royalty sale; runway through 2025.","TAMARACK trial modified: removed control arm; clinical update expected in 2024.","Lorigerlimab mCRPC data: 28.6% PSA50, 25.7% confirmed partial responses.","TZIELD approval milestone: two $15M payments received; two due by Sept 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-23-000058","json":"https://secwatch.observer/filing/0001125345-23-000058.json","markdown":"https://secwatch.observer/filing/0001125345-23-000058.md","text":"https://secwatch.observer/filing/0001125345-23-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000058/0001125345-23-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000058/mgnx-20230315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T01:40:28.685236+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b1499c11c6926f42ca6fb98e825ab3a68db9a430","claim":"MACROGENICS INC reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On March 15, 2023, MacroGenics, Inc. (the \"Company\") announced financial and operating results as of and for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000058/0001125345-23-000058-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}